Details of the Drug Combination

General Information of Drug Combination (ID: DCFF9VM)

Drug Combination Name
cycloheximide Naltrexone
Indication
Disease Entry Status REF
Hepatoblastoma Investigative [1]
Component Drugs cycloheximide   DMGDA3C Naltrexone   DMUL45H
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: HB3
Zero Interaction Potency (ZIP) Score: 3.795
Bliss Independence Score: 3.293
Loewe Additivity Score: 3.863
LHighest Single Agent (HSA) Score: 7.115

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of cycloheximide
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [2]
cycloheximide Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [15]
------------------------------------------------------------------------------------
cycloheximide Interacts with 120 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [16]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Increases Expression [8]
ATP-binding cassette sub-family C member 5 (ABCC5) OT34G4US MRP5_HUMAN Decreases Expression [8]
Transforming acidic coiled-coil-containing protein 1 (TACC1) OTGX20TE TACC1_HUMAN Increases Expression [8]
Trefoil factor 1 (TFF1) OTCYQH4F TFF1_HUMAN Increases Expression [8]
Receptor tyrosine-protein kinase erbB-2 (ERBB2) OTOAUNCK ERBB2_HUMAN Decreases Expression [8]
Amphiregulin (AREG) OTJFOR67 AREG_HUMAN Increases Expression [8]
Cyclin-A2 (CCNA2) OTPHHYZJ CCNA2_HUMAN Decreases Expression [8]
Insulin-like growth factor-binding protein 4 (IGFBP4) OT2HZRBD IBP4_HUMAN Increases Expression [8]
Insulin receptor substrate 1 (IRS1) OTNO82CU IRS1_HUMAN Decreases Expression [8]
CCN family member 3 (CCN3) OTOW5YL4 CCN3_HUMAN Increases Expression [8]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Increases Expression [17]
Aryl hydrocarbon receptor (AHR) OTFE4EYE AHR_HUMAN Decreases Expression [17]
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Decreases Activity [18]
Dynamin-1-like protein (DNM1L) OTXK1Q1G DNM1L_HUMAN Increases Expression [19]
Apoptotic protease-activating factor 1 (APAF1) OTJWIVY0 APAF_HUMAN Decreases Expression [19]
Glycosylphosphatidylinositol anchor attachment 1 protein (GPAA1) OTWVRR35 GPAA1_HUMAN Increases Expression [19]
Interleukin-1 alpha (IL1A) OTPSGILV IL1A_HUMAN Increases Expression [19]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Expression [19]
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1) OTM0GDTP IF2A_HUMAN Increases Expression [19]
Protein kinase C beta type (PRKCB) OTYQ0656 KPCB_HUMAN Decreases Expression [19]
Glia-derived nexin (SERPINE2) OTYF5340 GDN_HUMAN Increases Expression [19]
ETS domain-containing protein Elk-1 (ELK1) OTH9MXD6 ELK1_HUMAN Increases Expression [19]
Pleiotrophin (PTN) OTYC7M2A PTN_HUMAN Increases Expression [19]
CCN family member 2 (CCN2) OTC39NSU CCN2_HUMAN Increases Expression [19]
Kappa-type opioid receptor (OPRK1) OTXCZF4L OPRK_HUMAN Increases Expression [19]
Collagenase 3 (MMP13) OTY8BZIE MMP13_HUMAN Increases Expression [19]
Heterogeneous nuclear ribonucleoprotein H2 (HNRNPH2) OTMGP4J7 HNRH2_HUMAN Increases Expression [19]
Single-stranded DNA-binding protein, mitochondrial (SSBP1) OTH2PZWH SSBP_HUMAN Increases Expression [19]
Oxysterols receptor LXR-alpha (NR1H3) OT54YZ9I NR1H3_HUMAN Increases Expression [19]
Mitogen-activated protein kinase 7 (MAPK7) OTF7H7L7 MK07_HUMAN Increases Expression [19]
Pappalysin-1 (PAPPA) OTTTG9PG PAPP1_HUMAN Increases Expression [19]
SERTA domain-containing protein 2 (SERTAD2) OTYIG6TP SRTD2_HUMAN Increases Expression [19]
Next to BRCA1 gene 1 protein (NBR1) OTVRL7J9 NBR1_HUMAN Increases Expression [19]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Increases Expression [19]
5'-3' exonuclease PLD3 (PLD3) OTL07SP2 PLD3_HUMAN Increases Expression [19]
Synaptopodin (SYNPO) OTICDJAB SYNPO_HUMAN Increases Expression [19]
Transmembrane protein 263 (TMEM263) OTO1RSTS TM263_HUMAN Increases Expression [19]
Alpha-N-acetylneuraminide alpha-2,8-sialyltransferase (ST8SIA1) OTGND2YZ SIA8A_HUMAN Increases Expression [19]
Sororin (CDCA5) OTZLCQ5U CDCA5_HUMAN Increases Expression [19]
Retinoic acid receptor responder protein 2 (RARRES2) OT1BJE8K RARR2_HUMAN Increases Expression [19]
Solute carrier family 22 member 4 (SLC22A4) OT4LOVI9 S22A4_HUMAN Increases Expression [19]
CDC42 small effector protein 2 (CDC42SE2) OT8SG9I1 C42S2_HUMAN Increases Expression [19]
Myotubularin-related protein 7 (MTMR7) OT47NVYM MTMR7_HUMAN Increases Expression [19]
Small ribosomal subunit protein uS7m (MRPS7) OT57AX7G RT07_HUMAN Decreases Expression [19]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Decreases Expression [20]
Cytochrome P450 2A6 (CYP2A6) OT52TWG3 CP2A6_HUMAN Decreases Expression [21]
Amino acid transporter heavy chain SLC3A2 (SLC3A2) OTBR33M9 4F2_HUMAN Increases Expression [22]
NADPH--cytochrome P450 reductase (POR) OTVIDOCH NCPR_HUMAN Decreases Expression [23]
Tumor protein p53-inducible protein 11 (TP53I11) OTFPDYZU P5I11_HUMAN Decreases Expression [24]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [25]
Transcription regulator protein BACH1 (BACH1) OTY8004K BACH1_HUMAN Decreases Expression [26]
Proepiregulin (EREG) OTRM4NQY EREG_HUMAN Increases Expression [27]
CASP8 and FADD-like apoptosis regulator (CFLAR) OTX14BAS CFLAR_HUMAN Decreases Expression [28]
Autophagy-related protein 13 (ATG13) OTYMHNEJ ATG13_HUMAN Decreases Expression [11]
Protein phosphatase 1 regulatory subunit 15A (PPP1R15A) OTYG179K PR15A_HUMAN Decreases Expression [29]
Mitochondrial uncoupling protein 4 (SLC25A27) OTSBOPGD UCP4_HUMAN Increases Expression [30]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Increases Expression [27]
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Increases Expression [31]
Low-density lipoprotein receptor (LDLR) OTH559LU LDLR_HUMAN Decreases Expression [32]
Protransforming growth factor alpha (TGFA) OTPD1LL9 TGFA_HUMAN Increases Expression [27]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Decreases Activity [33]
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Decreases Expression [34]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Increases Expression [35]
Cytochrome P450 2E1 (CYP2E1) OTHQ17JG CP2E1_HUMAN Increases Degradation [36]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases Expression [37]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Decreases Expression [38]
Transcription factor AP-2-alpha (TFAP2A) OTMYT3NK AP2A_HUMAN Decreases Stability [39]
Beta-2 adrenergic receptor (ADRB2) OTSDOX4Q ADRB2_HUMAN Increases Expression [40]
Rho-related GTP-binding protein RhoC (RHOC) OTOLE1FT RHOC_HUMAN Decreases Expression [41]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [42]
Intestinal-type alkaline phosphatase (ALPI) OTTQ468O PPBI_HUMAN Decreases Activity [43]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [37]
E3 SUMO-protein ligase EGR2 (EGR2) OTAVQ78J EGR2_HUMAN Increases Expression [44]
Steroid hormone receptor ERR1 (ESRRA) OTTDTUSP ERR1_HUMAN Decreases Expression [45]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Increases Expression [37]
C-C motif chemokine 5 (CCL5) OTSCA5CK CCL5_HUMAN Increases Expression [37]
Nuclear factor NF-kappa-B p105 subunit (NFKB1) OTNRRD8I NFKB1_HUMAN Increases Expression [37]
Receptor tyrosine-protein kinase erbB-3 (ERBB3) OTRSST0A ERBB3_HUMAN Decreases Expression [27]
NF-kappa-B inhibitor alpha (NFKBIA) OTFT924M IKBA_HUMAN Decreases Expression [35]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Increases Phosphorylation [46]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Increases Phosphorylation [46]
Retinoblastoma-like protein 1 (RBL1) OTDEBFYC RBL1_HUMAN Decreases Expression [47]
Protein PML (PML) OT6SM2GD PML_HUMAN Decreases Degradation [48]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Increases Phosphorylation [49]
Pro-adrenomedullin (ADM) OT7T0TA4 ADML_HUMAN Increases Expression [50]
Receptor-type tyrosine-protein kinase FLT3 (FLT3) OTMSRYMK FLT3_HUMAN Decreases Expression [51]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Decreases Expression [52]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [53]
Cyclin-dependent kinase inhibitor 2A (CDKN2A) OTN0ZWAE CDN2A_HUMAN Increases Expression [54]
E3 ubiquitin-protein ligase RNF4 (RNF4) OTCMXQRE RNF4_HUMAN Decreases Expression [55]
Disintegrin and metalloproteinase domain-containing protein 17 (ADAM17) OTTM6KRB ADA17_HUMAN Decreases Stability [56]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Decreases Activity [57]
Urokinase plasminogen activator surface receptor (PLAUR) OTIRKKEQ UPAR_HUMAN Increases Expression [58]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Affects Localization [59]
Recombining binding protein suppressor of hairless (RBPJ) OTD7CUG0 SUH_HUMAN Decreases Expression [60]
Tight junction protein ZO-1 (TJP1) OTBDCUPK ZO1_HUMAN Decreases Expression [38]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Increases Expression [61]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Decreases Expression [62]
TAR DNA-binding protein 43 (TARDBP) OTVOSFWW TADBP_HUMAN Decreases Expression [63]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Decreases Expression [64]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [65]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Decreases Expression [66]
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Increases Degradation [13]
Protein NDRG1 (NDRG1) OTVO66BO NDRG1_HUMAN Decreases Expression [67]
Type II iodothyronine deiodinase (DIO2) OTGPNSLH IOD2_HUMAN Decreases Activity [68]
Sodium/iodide cotransporter (SLC5A5) OTU7E9G7 SC5A5_HUMAN Increases Expression [69]
Transcription termination factor 3, mitochondrial (MTERF3) OTVE8W7X MTEF3_HUMAN Decreases Expression [70]
NAD-dependent protein deacetylase sirtuin-1 (SIRT1) OTAYZMOY SIR1_HUMAN Decreases Expression [71]
Proheparin-binding EGF-like growth factor (HBEGF) OTLU00JS HBEGF_HUMAN Increases Expression [27]
Endothelial PAS domain-containing protein 1 (EPAS1) OTRE3O8U EPAS1_HUMAN Decreases Expression [72]
Repressor of RNA polymerase III transcription MAF1 homolog (MAF1) OTKB0N8Q MAF1_HUMAN Increases Degradation [73]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases Response To Substance [74]
MAP kinase-activated protein kinase 3 (MAPKAPK3) OT7IWJNI MAPK3_HUMAN Affects Response To Substance [14]
D-ribitol-5-phosphate cytidylyltransferase (CRPPA) OTC85K8Q ISPD_HUMAN Affects Response To Substance [14]
Rab9 effector protein with kelch motifs (RABEPK) OTCZSREH RABEK_HUMAN Affects Response To Substance [14]
Kremen protein 1 (KREMEN1) OTGJFSAC KREM1_HUMAN Affects Response To Substance [14]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Response To Substance [75]
Unconventional myosin-Id (MYO1D) OTP2RGPN MYO1D_HUMAN Affects Response To Substance [14]
Cation channel sperm-associated protein 4 (CATSPER4) OTXJ4E8J CTSR4_HUMAN Affects Response To Substance [14]
------------------------------------------------------------------------------------
⏷ Show the Full List of 120 DOT(s)
Indication(s) of Naltrexone
Disease Entry ICD 11 Status REF
Alcohol dependence 6C40.2 Approved [3]
Chronic alcoholism 6C40.2Z Approved [4]
Crohn disease DD70 Approved [5]
Gastroparesis DA41.00 Approved [5]
Inflammatory bowel disease DD72 Approved [5]
Obesity 5B81 Approved [5]
Ulcerative colitis DD71 Approved [5]
Human immunodeficiency virus infection 1C62 Phase 4 [6]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [7]
Chronic pain MG30 Investigative [5]
Naltrexone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Opioid receptor (OPR) TTN4QDT NOUNIPROTAC Antagonist [76]
------------------------------------------------------------------------------------
Naltrexone Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [77]
------------------------------------------------------------------------------------
Naltrexone Interacts with 9 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Nitric oxide synthase, inducible (NOS2) OTKKIOJ1 NOS2_HUMAN Decreases Activity [78]
Follitropin subunit beta (FSHB) OTGLS283 FSHB_HUMAN Increases Expression [79]
Lutropin subunit beta (LHB) OT5GBOVJ LSHB_HUMAN Increases Expression [79]
Mu-type opioid receptor (OPRM1) OT16AAT8 OPRM_HUMAN Affects Response To Substance [76]
Mu-type opioid receptor (OPRM1) OT16AAT8 OPRM_HUMAN Increases Response [76]
Sodium-dependent dopamine transporter (SLC6A3) OT39XG28 SC6A3_HUMAN Affects Response To Substance [80]
Gamma-aminobutyric acid receptor subunit beta-2 (GABRB2) OTAOZIGX GBRB2_HUMAN Affects Response To Substance [81]
D(2) dopamine receptor (DRD2) OTBLXKEG DRD2_HUMAN Affects Response To Substance [81]
Gamma-aminobutyric acid receptor subunit alpha-6 (GABRA6) OTX4UC3O GBRA6_HUMAN Affects Response To Substance [81]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DOT(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5433).
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 074918.
5 Naltrexone FDA Label
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1639).
7 ClinicalTrials.gov (NCT04365985) Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19. U.S. National Institutes of Health.
8 Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
9 Estrogen regulation of the glucuronidation enzyme UGT2B15 in estrogen receptor-positive breast cancer cells. Endocrinology. 2006 Aug;147(8):3843-50.
10 Inhibition of thymidine phosphorylase expression by Hsp90 inhibitor potentiates the cytotoxic effect of salinomycin in human non-small-cell lung cancer cells. Toxicology. 2019 Apr 1;417:54-63.
11 Suppressed translation and ULK1 degradation as potential mechanisms of autophagy limitation under prolonged starvation. Autophagy. 2016 Nov;12(11):2085-2097. doi: 10.1080/15548627.2016.1226733. Epub 2016 Sep 14.
12 Cinobufagin restrains the growth and triggers DNA damage of human hepatocellular carcinoma cells via proteasome-dependent degradation of thymidylate synthase. Chem Biol Interact. 2022 Jun 1;360:109938. doi: 10.1016/j.cbi.2022.109938. Epub 2022 Apr 12.
13 Induction of vascular endothelial growth factor expression and hypoxia-inducible factor 1alpha protein by the oxidative stressor arsenite. J Biol Chem. 2001 Dec 21;276(51):48066-76. doi: 10.1074/jbc.M106282200. Epub 2001 Oct 18.
14 Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study. Environ Health Perspect. 2015 May;123(5):458-66. doi: 10.1289/ehp.1408775. Epub 2015 Jan 13.
15 Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012 Aug 15;19(11):977-87.
16 A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line. Mol Pharmacol. 1995 Oct;48(4):682-9.
17 Superinduction of CYP1A1 in MCF10A cultures by cycloheximide, anisomycin, and puromycin: a process independent of effects on protein translation and unrelated to suppression of aryl hydrocarbon receptor proteolysis by the proteasome. Mol Pharmacol. 2004 Oct;66(4):936-47.
18 Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition. J Med Chem. 2006 Feb 23;49(4):1413-9.
19 Comparative analysis of AhR-mediated TCDD-elicited gene expression in human liver adult stem cells. Toxicol Sci. 2009 Nov;112(1):229-44.
20 The effect of interferon-alpha on the expression of cytochrome P450 3A4 in human hepatoma cells. Toxicol Appl Pharmacol. 2011 Jun 1;253(2):130-6.
21 Metabolism of bilirubin by human cytochrome P450 2A6. Toxicol Appl Pharmacol. 2012 May 15;261(1):50-8.
22 Aryl hydrocarbon receptor-dependent up-regulation of the heterodimeric amino acid transporter LAT1 (SLC7A5)/CD98hc (SLC3A2) by diesel exhaust particle extract in human bronchial epithelial cells. Toxicol Appl Pharmacol. 2016 Jan 1;290:74-85.
23 Instability of the human cytochrome p450 reductase A287P variant is the major contributor to its antley-bixler syndrome-like phenotype. J Biol Chem. 2016 Sep 23;291(39):20487-502.
24 Possible roles of a tumor suppressor gene PIG11 in hepatocarcinogenesis and As2O3-induced apoptosis in liver cancer cells. J Gastroenterol. 2009;44(5):460-9. doi: 10.1007/s00535-009-0030-1. Epub 2009 Apr 1.
25 Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst. 2004 Dec 1;96(23):1769-80. doi: 10.1093/jnci/djh322.
26 Tetrachlorobenzoquinone induces Nrf2 activation via rapid Bach1 nuclear export/ubiquitination and JNK-P62 signaling. Toxicology. 2016 Jul 1;363-364:48-57. doi: 10.1016/j.tox.2016.07.002. Epub 2016 Jul 5.
27 The DNA damaging agent VP16 induces the expression of a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced. Mol Cell Biochem. 2004 May;260(1-2):129-35. doi: 10.1023/b:mcbi.0000026063.96267.98.
28 Inhibition of phosphatidylinositol 3-kinase sensitizes vascular endothelial cells to cytokine-initiated cathepsin-dependent apoptosis. J Biol Chem. 2003 Jun 6;278(23):21295-306. doi: 10.1074/jbc.M212837200. Epub 2003 Mar 27.
29 Chronic oxidative stress promotes GADD34-mediated phosphorylation of the TAR DNA-binding protein TDP-43, a modification linked to neurodegeneration. J Biol Chem. 2018 Jan 5;293(1):163-176. doi: 10.1074/jbc.M117.814111. Epub 2017 Nov 6.
30 Transcriptional regulation of UCP4 by NF-kappaB and its role in mediating protection against MPP+ toxicity. Free Radic Biol Med. 2010 Jul 15;49(2):192-204. doi: 10.1016/j.freeradbiomed.2010.04.002. Epub 2010 Apr 9.
31 Induction of c-fos proto-oncogene in mesangial cells by cadmium. J Biol Chem. 1998 Jan 2;273(1):73-9. doi: 10.1074/jbc.273.1.73.
32 Quercetin up-regulates LDL receptor expression in HepG2 cells. Phytother Res. 2012 Nov;26(11):1688-94. doi: 10.1002/ptr.4646. Epub 2012 Mar 3.
33 Identification and Profiling of Environmental Chemicals That Inhibit the TGF/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11.
34 Xenoestrogens alter estrogen receptor (ER) intracellular levels. PLoS One. 2014 Feb 20;9(2):e88961. doi: 10.1371/journal.pone.0088961. eCollection 2014.
35 IkappaBalpha (inhibitory kappaBalpha) identified as labile repressor of MnSOD (manganese superoxide dismutase) expression. Biochem J. 2004 Dec 15;384(Pt 3):543-9. doi: 10.1042/BJ20040714.
36 Characterization of cytochrome P4502E1 turnover in transfected HepG2 cells expressing human CYP2E1. Arch Biochem Biophys. 1997 May 1;341(1):25-33. doi: 10.1006/abbi.1997.9907.
37 The synthetic bile acid-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide suppresses TNF-induced liver injury. J Hepatol. 2011 Apr;54(4):674-84. doi: 10.1016/j.jhep.2010.07.028. Epub 2010 Sep 27.
38 Effect of cytokines on ICAM-1 and ZO-1 expression on human airway epithelial cells. Cell Biol Int. 2005 Sep;29(9):768-77. doi: 10.1016/j.cellbi.2005.05.002.
39 Linc-ROR drive adriamycin resistance by targeting AP-2/Wnt/-catenin axis in hepatocellular carcinoma. Cell Biol Toxicol. 2023 Aug;39(4):1735-1752. doi: 10.1007/s10565-022-09777-3. Epub 2022 Dec 28.
40 Dual regulation of 2-adrenoceptor messenger RNA expression in human lung fibroblasts by 2-cAMP signaling; delayed upregulated inhibitors oppose a rapid in onset, direct stimulation of gene expression. Naunyn Schmiedebergs Arch Pharmacol. 2014 Jul;387(7):649-57. doi: 10.1007/s00210-014-0971-7. Epub 2014 Apr 8.
41 RNF168 suppresses the cancer stem cell-like traits of nonsmall cell lung cancer cells by mediating RhoC ubiquitination. Environ Toxicol. 2022 Mar;37(3):603-611. doi: 10.1002/tox.23428. Epub 2021 Dec 7.
42 Inhibition of breast cancer cell growth and induction of cell death by 1,1-bis(3'-indolyl)methane (DIM) and 5,5'-dibromoDIM. Cancer Lett. 2006 May 18;236(2):198-212. doi: 10.1016/j.canlet.2005.05.036. Epub 2005 Jul 26.
43 Deoxynivalenol affects in vitro intestinal epithelial cell barrier integrity through inhibition of protein synthesis. Toxicol Appl Pharmacol. 2010 Jun 15;245(3):291-8. doi: 10.1016/j.taap.2010.03.012. Epub 2010 Apr 1.
44 Redox-sensitive regulation of gene expression in human primary macrophages exposed to inorganic arsenic. J Cell Biochem. 2009 Jun 1;107(3):537-47. doi: 10.1002/jcb.22155.
45 ERR contributes to HDAC6-induced chemoresistance of osteosarcoma cells. Cell Biol Toxicol. 2023 Jun;39(3):813-825. doi: 10.1007/s10565-021-09651-8. Epub 2021 Sep 15.
46 Receptors for bitter, sweet and umami taste couple to inhibitory G protein signaling pathways. Eur J Pharmacol. 2004 Apr 12;489(3):139-49. doi: 10.1016/j.ejphar.2004.03.004.
47 Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology. 2010 May;138(5):1920-30. doi: 10.1053/j.gastro.2010.01.007. Epub 2010 Jan 25.
48 Solubility shift and SUMOylaltion of promyelocytic leukemia (PML) protein in response to arsenic(III) and fate of the SUMOylated PML. Toxicol Appl Pharmacol. 2015 Sep 15;287(3):191-201. doi: 10.1016/j.taap.2015.05.018. Epub 2015 Jun 3.
49 Akt activation by Ca(2+)/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells. J Biol Chem. 2017 Aug 25;292(34):14188-14204. doi: 10.1074/jbc.M117.778464. Epub 2017 Jun 20.
50 Induction of adrenomedullin during hypoxia in cultured human glioblastoma cells. J Neurochem. 2000 Nov;75(5):1826-33. doi: 10.1046/j.1471-4159.2000.0751826.x.
51 Arsenic trioxide induces autophagic degradation of the FLT3-ITD mutated protein in FLT3-ITD acute myeloid leukemia cells. J Cancer. 2020 Mar 13;11(12):3476-3482. doi: 10.7150/jca.29751. eCollection 2020.
52 Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
53 G1P3, an interferon inducible gene 6-16, is expressed in gastric cancers and inhibits mitochondrial-mediated apoptosis in gastric cancer cell line TMK-1 cell. Cancer Immunol Immunother. 2005 Aug;54(8):729-40. doi: 10.1007/s00262-004-0645-2. Epub 2005 Feb 1.
54 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) exposure of normal human dermal fibroblasts results in AhR-dependent and -independent changes in gene expression. Toxicol Appl Pharmacol. 2007 Apr 1;220(1):9-17. doi: 10.1016/j.taap.2006.12.002. Epub 2006 Dec 15.
55 Arsenic-induced SUMO-dependent recruitment of RNF4 into PML nuclear bodies. Mol Biol Cell. 2010 Dec;21(23):4227-39. doi: 10.1091/mbc.E10-05-0449. Epub 2010 Oct 13.
56 Antiviral Potential of Small Molecules Cordycepin, Thymoquinone, and N6, N6-Dimethyladenosine Targeting SARS-CoV-2 Entry Protein ADAM17. Molecules. 2022 Dec 19;27(24):9044. doi: 10.3390/molecules27249044.
57 A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
58 Interferon-alpha (Intron A) upregulates urokinase-type plasminogen activator receptor gene expression. Cancer Immunol Immunother. 2002 Jul;51(5):248-54. doi: 10.1007/s00262-002-0275-5. Epub 2002 Apr 9.
59 Inactivation of IkappaB contributes to transcriptional activation of spermidine/spermine N(1)-acetyltransferase. Mol Carcinog. 2006 Sep;45(9):685-93. doi: 10.1002/mc.20239.
60 Presenilin-2 regulates the degradation of RBP-Jk protein through p38 mitogen-activated protein kinase. J Cell Sci. 2012 Mar 1;125(Pt 5):1296-308. doi: 10.1242/jcs.095984. Epub 2012 Feb 2.
61 Dexamethasone suppresses apoptosis in a human gastric cancer cell line through modulation of bcl-x gene expression. FEBS Lett. 1997 Sep 22;415(1):11-5. doi: 10.1016/s0014-5793(97)01083-1.
62 Interleukin-15 delays human neutrophil apoptosis by intracellular events and not via extracellular factors: role of Mcl-1 and decreased activity of caspase-3 and caspase-8. J Leukoc Biol. 2004 May;75(5):893-900. doi: 10.1189/jlb.1103585. Epub 2004 Feb 24.
63 Disease-associated mutations of TDP-43 promote turnover of the protein through the proteasomal pathway. Mol Neurobiol. 2014 Dec;50(3):1049-58. doi: 10.1007/s12035-014-8644-6. Epub 2014 Jan 30.
64 Enhanced p62-NRF2 Feedback Loop due to Impaired Autophagic Flux Contributes to Arsenic-Induced Malignant Transformation of Human Keratinocytes. Oxid Med Cell Longev. 2019 Oct 30;2019:1038932. doi: 10.1155/2019/1038932. eCollection 2019.
65 Resistance to Fas-mediated apoptosis is restored by cycloheximide through the downregulation of cellular FLIPL in NK/T-cell lymphoma. Lab Invest. 2005 Jul;85(7):874-84. doi: 10.1038/labinvest.3700291.
66 Nrf2 Expression and Apoptosis in Quercetin-treated Malignant Mesothelioma Cells. Mol Cells. 2015 May;38(5):416-25. doi: 10.14348/molcells.2015.2268. Epub 2015 Apr 21.
67 NDRG1 inhibition sensitizes osteosarcoma cells to combretastatin A-4 through targeting autophagy. Cell Death Dis. 2017 Sep 14;8(9):e3048. doi: 10.1038/cddis.2017.438.
68 The human type 2 iodothyronine deiodinase is a selenoprotein highly expressed in a mesothelioma cell line. J Biol Chem. 2001 Aug 10;276(32):30183-7. doi: 10.1074/jbc.C100325200. Epub 2001 Jun 25.
69 Protein synthesis inhibitors, in synergy with 5-azacytidine, restore sodium/iodide symporter gene expression in human thyroid adenoma cell line, KAK-1, suggesting trans-active transcriptional repressor. J Clin Endocrinol Metab. 2007 Mar;92(3):1080-7. doi: 10.1210/jc.2006-2106. Epub 2006 Dec 12.
70 MTERF3 contributes to MPP+-induced mitochondrial dysfunction in SH-SY5Y cells. Acta Biochim Biophys Sin (Shanghai). 2022 Aug 25;54(8):1113-1121. doi: 10.3724/abbs.2022098.
71 JNK activation-mediated nuclear SIRT1 protein suppression contributes to silica nanoparticle-induced pulmonary damage via p53 acetylation and cytoplasmic localisation. Toxicology. 2019 Jul 1;423:42-53. doi: 10.1016/j.tox.2019.05.003. Epub 2019 May 11.
72 A MALAT1/HIF-2 feedback loop contributes to arsenite carcinogenesis. Oncotarget. 2016 Feb 2;7(5):5769-87. doi: 10.18632/oncotarget.6806.
73 The RNA polymerase III repressor MAF1 is regulated by ubiquitin-dependent proteasome degradation and modulates cancer drug resistance and apoptosis. J Biol Chem. 2019 Dec 13;294(50):19255-19268. doi: 10.1074/jbc.RA119.008849. Epub 2019 Oct 23.
74 Position of STAT-1 alpha in cycloheximide-dependent apoptosis triggered by TNF-alpha in human colorectal COLO 205 cancer cell line; role of polyphenolic compounds. J Physiol Pharmacol. 2005 Jun;56 Suppl 3:119-41.
75 Reduced level of ribonucleotide reductase R2 subunits increases dependence on homologous recombination repair of cisplatin-induced DNA damage. Mol Pharmacol. 2011 Dec;80(6):1000-12. doi: 10.1124/mol.111.074708. Epub 2011 Aug 29.
76 An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb;65(2):135-44.
77 In vivo chronic exposure to heroin or naltrexone selectively inhibits liver microsome formation of estradiol-3-glucuronide in the rat. Biochem Pharmacol. 2008 Sep 1;76(5):672-9.
78 Low dose naltrexone therapy in multiple sclerosis. Med Hypotheses. 2005;64(4):721-4.
79 Chronic naltrexone treatment induces desensitization of the luteinizing hormone pulse generator for opioid blockade in hyperprolactinemic patients. J Clin Endocrinol Metab. 1995 May;80(5):1739-42. doi: 10.1210/jcem.80.5.7745028.
80 Association between the Stin2 VNTR polymorphism of the serotonin transporter gene and treatment outcome in alcohol-dependent patients. Alcohol Alcohol. 2008 Sep-Oct;43(5):516-22. doi: 10.1093/alcalc/agn048. Epub 2008 Jun 14.
81 Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol. 2009 Jul;14(3):328-37.